Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults.

[1]  R. Isturiz,et al.  Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[2]  C. Whitney,et al.  Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2014, MMWR. Morbidity and mortality weekly report.

[3]  S. Pelton,et al.  Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  K. LaPlante,et al.  Epidemiology of Pneumococcal Disease in a National Cohort of Older Adults , 2014, Infectious Diseases and Therapy.

[5]  Kimberly M. Shea,et al.  Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions , 2014, Open forum infectious diseases.

[6]  Craig M. Hales,et al.  Noninfluenza Vaccination Coverage Among Adults — United States, 2012 , 2014, MMWR. Morbidity and mortality weekly report.

[7]  W. Schaffner,et al.  Nearly Complete Elimination of the 7-valent Pneumococcal Conjugate Vaccine Serotypes in Tennessee , 2013, The Pediatric infectious disease journal.

[8]  S. Deeks,et al.  Have changing pneumococcal vaccination programmes impacted disease in Ontario? , 2013, Vaccine.

[9]  S. Kaplan,et al.  Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine , 2013, The Pediatric infectious disease journal.

[10]  W. Schaffner,et al.  Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Craig M. Hales,et al.  Noninfluenza Vaccination Coverage Among Adults — United States, 2011 , 2013, MMWR. Morbidity and mortality weekly report.

[12]  M. Gilmour,et al.  Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. , 2012, Canadian journal of microbiology.

[13]  H. B. DemczukWalter,et al.  Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010 , 2012 .

[14]  C. Byington,et al.  The Changing Epidemiology of Invasive Pneumococcal Disease at a Tertiary Children's Hospital Through the 7-valent Pneumococcal Conjugate Vaccine Era: A Case for Continuous Surveillance , 2012, The Pediatric infectious disease journal.

[15]  W. Schaffner,et al.  Risk Factors for Invasive Pneumococcal Disease in Children in the Era of Conjugate Vaccine Use , 2010, Pediatrics.

[16]  M. Joffe,et al.  Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults , 2008, Epidemiology and Infection.

[17]  A. Schuchat,et al.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. , 2001, JAMA.

[18]  A. Cross,et al.  Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. , 1986, The New England journal of medicine.